Compositions, methods and devices for intranasal administration of Rasagiline or a pharmaceutically acceptable salt thereof are disclosed. The compositions, devices and methods are for treating depression, Parkinsons disease and/or motor and depression symptoms associated with Parkinsons disease, by intranasal administration of an amount of Rasagiline or a pharmaceutically acceptable salt thereof that is sufficient to inhibit depressive illness in the subject and/or is sufficient to inhibit MAO-A in the brain of a subject.
